Bayer AG v. Prinston: Rivaroxaban Patent Case Dismissed
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Bayer AG v. Prinston Pharmaceutical, Inc. |
| Case Number | 1:24-cv-00336 (Fed. Dist. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Mar 2024 – Jan 2026 665 days |
| Outcome | Case Resolution: Dismissal with Prejudice |
| Patents at Issue | |
| Accused Products | Prinston’s rivaroxaban tablets (2.5 mg, 10 mg, 15 mg, and 20 mg) |
Case Overview
The Parties
⚖️ Plaintiffs
Bayer AG is a German multinational pharmaceutical company. Co-plaintiff Janssen Pharmaceuticals, Inc. is a Johnson & Johnson subsidiary and co-holder of key Xarelto patents.
🛡️ Defendant
U.S.-based generic drug manufacturer and subsidiary of Zhejiang Huahai Pharmaceutical Co., focused on Abbreviated New Drug Application (ANDA) pathways.
The Patents at Issue
This litigation involved two critical patents protecting rivaroxaban, the active ingredient in the blockbuster anticoagulant Xarelto. These patents are fundamental to the commercial formulation advantage held by Bayer and Janssen.
- • U.S. Patent No. 9,539,218 B2 — Formulation patent covering rivaroxaban compositions
- • U.S. Patent No. 10,828,310 B2 — Continuation-family patent extending protection over dosage and administration methods
Developing a generic pharmaceutical?
Check if your formulation might infringe these or related patents before market entry.
The Verdict & Legal Analysis
Outcome
On January 8, 2026, the case concluded with a joint stipulation of dismissal. Plaintiffs’ claims were dismissed with prejudice, meaning Bayer and Janssen cannot re-litigate these specific infringement claims against Prinston. Prinston’s counterclaims were dismissed without prejudice, preserving its ability to assert invalidity or other defenses in future proceedings.
Legal Significance
The dismissal with prejudice for the plaintiffs typically signals a favorable resolution for the patent holder, likely involving a licensing agreement or a defined generic market entry date. The preservation of Prinston’s counterclaims allows them to reassert invalidity positions in other venues, such as the PTAB (Patent Trial and Appeal Board).
This outcome does not create binding precedent on patent validity, but it reinforces the commercial value of the asserted patents by precluding further challenge from Prinston in this litigation posture. The resolution reflects the strategic complexities of Hatch-Waxman Act litigation in the pharmaceutical industry.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical formulation. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications for generic pharmaceutical development.
- View the Xarelto patent family and related patents
- Analyze active formulation patents in this space
- Identify key players in anticoagulant IP
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic drug or formulation.
- Input your formulation details or technical features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report
High Risk Area
Rivaroxaban and Factor Xa inhibitor formulations
Xarelto Patent Family
Multiple active patents and continuations
Negotiated Entry
Common resolution in pharma ANDA cases
✅ Key Takeaways
Asymmetric dismissal terms (with/without prejudice) in ANDA settlements are strategically significant and should be carefully negotiated.
Search related case law →Continuation patent families extend enforcement timelines; assert multiple family members to maximize leverage in pharma disputes.
Explore precedents →Delaware remains the venue of choice for pharmaceutical patent litigation; local counsel selection is critical for ANDA cases.
Identify top IP litigators →Frequently Asked Questions
U.S. Patent Nos. 9,539,218 B2 and 10,828,310 B2, both directed to rivaroxaban formulations and related to the branded drug Xarelto.
Plaintiffs’ infringement claims were dismissed with prejudice — permanently barring re-litigation — while Prinston’s counterclaims were dismissed without prejudice, preserving its right to reassert invalidity or other defenses in future proceedings.
While not precedential on validity or infringement, the resolution may reflect negotiated market entry terms and signals continued patent holder leverage in the Hatch-Waxman ANDA context for high-value cardiovascular formulations.
Ready to Strengthen Your Pharmaceutical Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case Locator – Case No. 1:24-cv-00336
- U.S. Patent and Trademark Office — Patent Full-Text Database
- FDA — Hatch-Waxman Act Information
- U.S. Patent and Trademark Office — PTAB Resources
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.